| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-04-06 | THR-149 | diabetic macular edema | preclinical | Thrombogenics (Belgium) | Ophtalmological diseases |
| 2018-04-05 | Tau Morphomers | Alzheimer's disease | 1 | AC Immune (Switzerland) | Neurodegenerative diseases |
| 2018-04-04 | THR-317 | diabetic macular edema | 2 | Thrombogenics (Belgium) | Ophtalmological diseases |
| 2018-04-04 | SB-913 (adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene) | mucopolysaccharidosis type II (Hunter's syndrome) | preclinical | Sangamo Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2018-04-03 | sparsentan (RE-021) | focal segmental glomerulosclerosis (FSGS) | 3 | Retrophin (USA - CA) | Rare diseases - Kidney diseases - Renal diseases |
| 2018-03-29 | FATE-NK100 (adaptive NK cell therapy) | ovarian cancer resistant to, or recurrent on, platinum-based treatment | 1 | Fate Therapeutics (USA - CA) | Cancer - Oncology |
| 2018-03-28 | FPA150 | advanced or metastatic breast, ovarian, endometrial and bladder cancers | 1 | Five Prime Therapeutics (USA - CA) | Cancer - Oncology |
| 2018-03-26 | ALX-0061 - vobarilizumab | systemic lupus erythematosus (SLE) | 2 | Ablynx (Belgium) AbbVie (USA -IL) | Autoimmune diseases |
| 2018-03-26 | GNbAC1 | relapsing-remitting multiple sclerosis (RRMS) | 2b | GeNeuro (Switzerland) | Autoimmune diseases - Neurodegenerative diseases |
| 2018-03-22 | rovalpituzumab tesirine (Rova-T) | relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer (SCLC) | 2 | Stemcentrx (USA - CA), now AbbVie (USA - IL) | Cancer - Oncology - Rare diseases |
| 2018-03-19 | BGS-649 (leflutrozole) | hypogonadotropic hypogonadism (HH) | 2b | Mereo Biopharma (UK) | Endocrine diseases - Hormonal diseases - Metabolic diseases |
| 2018-03-19 | ProTmune™ | prevention of acute graft-versus-host disease (GvHD) | 1-2 | Fate Therapeutics (USA - CA) | Transplantation |
| 2018-03-15 | alpha-synuclein-PET tracers | Parkinson's disease | preclinical | AC Immune (Switzerland) | Neurodegenerative diseases |
| 2018-03-12 | G100 and pembrolizumab | follicular lymphoma | 1-2 | Immune Design (USA - MA) Merck&Co (USA - NJ) | Cancer - Oncology |
| 2018-03-12 | CMB305 (LV305 and G305) - dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene05 | soft tissue sarcoma | 1-2 | Immune Design (USA - MA) | Cancer - Oncology |
| 2018-03-08 | IFX-1 | moderate to severe Hidradenitis Suppurativa (HS) | 2b | InflaRx (Germany) | Dermatological diseases - Inflammatory diseases |
| 2018-03-07 | DTX301 | ornithine transcarbamylase deficiency | 1-2 | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2018-03-03 | DX-2930 - lanadelumab | type 1 and type 2 hereditary angioedema (HAE) | 3 | Dyax (USA - MA), now Shire (UK - USA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2018-02-21 | CAR-Treg manufacturing process | - | Txcell (France) | Technology - Services - Autoimmune diseases - Immunological diseases | |
| 2018-02-20 | FATE-NK100 (adaptive NK cell therapy) | advanced solid tumors | 1 | Fate Therapeutics (USA - CA) | Cancer - Oncology |
